Bill > HB4354

This bill amends the Insurance Code of 1956 to require health insurance policies in Michigan that cover orally administered and intravenously/injected anticancer medications to ensure that the financial requirements, such as co-pays and coinsurance, for orally administered anticancer medications are not more restrictive than for intravenously/injected anticancer medications. The bill also limits the maximum co-pay for orally administered anticancer medications to $150 per 30-day supply, with annual adjustments based on the prescription drug index of the Consumer Price Index. The bill prohibits insurers from increasing cost-sharing requirements or reclassifying benefits to avoid compliance, and allows insurers to apply certain utilization management techniques. The bill applies to policies delivered, issued, or renewed after December 31, 2022, and is tied to the enactment of House Bill 4347.